COMPARE · Data as of August 21, 2026
ANIP vs HIMS
Verdict: Side-by-side breakdown using the Bull Rankings model. ANIP scored 79.6, HIMS scored 39.3 — ANIP leads.
Compare another set
ANIP
ANI Pharmaceuticals, Inc.
79.6
$75.35 · $1.7B
fundamentals as of
Score gap
40.3
ANIP leads
HIMS
Hims & Hers Health, Inc.
39.3
$31.13 · $7.3B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- Fastest growthANIP+30.9%
- Strongest balance sheetANIP1.05
- Highest qualityANIP66 / 100
- Largest discount to fair valueANIP-46%
Side by side · every name on one set of axes
The model, pillar by pillar (0–100 each)
ANIP
stronger →← stronger
HIMS
66
Qualityreturns · margins · balance sheet
23
94
Growthrevenue & earnings expansion
93
81
Valuevaluation vs sector peers
29
ANIP is stronger on 3 of 3 pillars.
Fundamentals, head-to-head
ANIP
HIMS
$173mC
FCF
$62mC-
+30.9%A
Rev
+28.0%A-
1.05C
D/E
4.77D
16.4xA-
P/E
—
1.26B
PEG
2.15C
—
P/S
2.8xB+
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
ANIP
HIMS
46% below
Price vs fair valuelower is cheaper
777% above
~-6%/yr
Growth the price implies10-yr FCF · lower = less priced in
>60%/yr
+62%
1-yr DCF upside
-91%
+85%
5-yr DCF upside
-89%
+123%
10-yr DCF upside
-84%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
ANIP
No notable signals flagged.
HIMS
Why this score
- Diluting shareholders
The companies
ANIPANI Pharmaceuticals, Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $1.7b. Down 24% from 52-week high of $99.50 — deep drawdown territory. Revenue growing +31% — in hypergrowth territory. 8 sell-side analysts rate this a Buy with a mean 1-yr target of $108.38 (implying +44% upside).
Moat
ROE 18% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 160% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
HIMSHims & Hers Health, Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $7.3b. Down 52% from 52-week high of $65.30 — deep drawdown territory. Revenue growing +28% — in hypergrowth territory. 13 sell-side analysts rate this a Hold with a mean 1-yr target of $30.85 (implying -1% upside).
Moat
Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
D/E 4.77 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Currently unprofitable (margin -5.5%) — path to GAAP profitability is the core thesis risk. Down 52% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where ANIP and HIMS diverge
On the headline score the gap is 40.3 points in favor of ANIP. The widest single difference is Value, where ANIP leads by 52.4 points.
- ValueANIP 81.2 · HIMS 28.8ANIP +52.4
- QualityANIP 66.2 · HIMS 22.7ANIP +43.5
- GrowthANIP 93.8 · HIMS 92.8level
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.